ES3063941T3 - Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma - Google Patents
Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphomaInfo
- Publication number
- ES3063941T3 ES3063941T3 ES21783084T ES21783084T ES3063941T3 ES 3063941 T3 ES3063941 T3 ES 3063941T3 ES 21783084 T ES21783084 T ES 21783084T ES 21783084 T ES21783084 T ES 21783084T ES 3063941 T3 ES3063941 T3 ES 3063941T3
- Authority
- ES
- Spain
- Prior art keywords
- approximately
- compound
- lymphoma
- formula
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070984P | 2020-08-27 | 2020-08-27 | |
| PCT/US2021/047778 WO2022047051A1 (en) | 2020-08-27 | 2021-08-26 | Use of a dhodh inhibitor compound in combination cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3063941T3 true ES3063941T3 (en) | 2026-04-21 |
Family
ID=78000775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21783084T Active ES3063941T3 (en) | 2020-08-27 | 2021-08-26 | Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230285365A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4203950B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7734742B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230078997A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116847874B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023003493A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3190511A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3063941T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022047051A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3060390A1 (en) | 2017-04-24 | 2018-11-01 | Aurigene Discovery Technologies Limited | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
| CA3091792A1 (en) | 2018-02-20 | 2019-08-29 | Agios Pharmaceuticals, Inc. | Methods of use for trisubstituted benzotriazole derivatives |
| BR112021012305A2 (pt) * | 2018-12-21 | 2021-10-05 | Les Laboratoires Servier Sas | Formas cristalinas e salinas de um composto orgânico e composições farmacêuticas das mesmas |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2694829T3 (es) | 2013-02-25 | 2018-12-27 | Aurigene Discovery Technologies Limited | Derivados de benzotriazol trisustituido como inhibidores de dihidroorotato oxigenasa |
| US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| CN106687139A (zh) * | 2014-07-14 | 2017-05-17 | 吉利德科学公司 | 用于治疗癌症的组合 |
| WO2016166761A1 (en) * | 2015-04-14 | 2016-10-20 | Tiltan Pharma Ltd. | Combination therapies and uses thereof in the treatment of cancer |
| CA3060390A1 (en) * | 2017-04-24 | 2018-11-01 | Aurigene Discovery Technologies Limited | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
| US20180369206A1 (en) * | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| CA3091792A1 (en) * | 2018-02-20 | 2019-08-29 | Agios Pharmaceuticals, Inc. | Methods of use for trisubstituted benzotriazole derivatives |
| WO2019197269A1 (en) * | 2018-04-11 | 2019-10-17 | Bayer Aktiengesellschaft | Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer |
| KR20210003789A (ko) * | 2018-05-04 | 2021-01-12 | 포톨라 파마슈티컬스, 인코포레이티드 | 림프종을 치료하는 방법 |
| WO2020109625A1 (en) * | 2018-11-30 | 2020-06-04 | Fondazione Centro San Raffaele | Combined treatment of primary central nervous system lymphoma |
| BR112021012305A2 (pt) * | 2018-12-21 | 2021-10-05 | Les Laboratoires Servier Sas | Formas cristalinas e salinas de um composto orgânico e composições farmacêuticas das mesmas |
-
2021
- 2021-08-26 KR KR1020237004006A patent/KR20230078997A/ko active Pending
- 2021-08-26 US US18/015,396 patent/US20230285365A1/en active Pending
- 2021-08-26 WO PCT/US2021/047778 patent/WO2022047051A1/en not_active Ceased
- 2021-08-26 BR BR112023003493A patent/BR112023003493A2/pt unknown
- 2021-08-26 ES ES21783084T patent/ES3063941T3/es active Active
- 2021-08-26 EP EP21783084.3A patent/EP4203950B1/en active Active
- 2021-08-26 JP JP2023512718A patent/JP7734742B2/ja active Active
- 2021-08-26 CN CN202180052749.9A patent/CN116847874B/zh active Active
- 2021-08-26 CA CA3190511A patent/CA3190511A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022047051A1 (en) | 2022-03-03 |
| US20230285365A1 (en) | 2023-09-14 |
| CN116847874A (zh) | 2023-10-03 |
| EP4203950B1 (en) | 2026-02-18 |
| CN116847874B (zh) | 2026-07-03 |
| BR112023003493A2 (pt) | 2023-04-11 |
| JP2023540206A (ja) | 2023-09-22 |
| JP7734742B2 (ja) | 2025-09-05 |
| EP4203950A1 (en) | 2023-07-05 |
| EP4203950C0 (en) | 2026-02-18 |
| KR20230078997A (ko) | 2023-06-05 |
| CA3190511A1 (en) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025000105A (es) | Inhibidor de kras g12c para el tratamiento del cancer | |
| PE20221154A1 (es) | Combinacion farmaceutica de inhibidores de prmt5 | |
| CL2023000847A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| WO2018102687A3 (en) | Combination therapy for treating cancer | |
| UY27481A1 (es) | Alquinos como inhibidores de metaloproteinasa de matriz | |
| NO2012015I2 (no) | Dapoxetine | |
| ECSP22089498A (es) | Inhibidores de il4i1 y métodos de uso | |
| CL2021002217A1 (es) | Composición farmacéutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda | |
| MX2022016554A (es) | Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida. | |
| WO2021041539A3 (en) | Pyrido-indole analogues as gpx4 inhibitors | |
| MX2024003926A (es) | Terapia de combinacion que utiliza un inhibidor de ptpn11 y un inhibidor de kras g12c. | |
| MX2022003830A (es) | Compuesto de n-(1h-imidazol-2-il)benzamida y composicion farmaceutica que comprende el mismo como ingrediente activo. | |
| MX2023010314A (es) | Terapia de combinación usando un inhibidor de malt1 y un inhibidor de btk. | |
| PE20212333A1 (es) | Compuestos de acido ascorbico y quinona en combinacion con un agente antiparasitario para el tratamiento de una enfermedad parasitaria | |
| MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
| BR112023003493A2 (pt) | Uso de um composto inibidor de dhodh em terapia de câncer de combinação | |
| BR112022026519A2 (pt) | Uso de um composto inibidor de dhodh em terapia de câncer de combinação | |
| MX2024010644A (es) | Uso de iptacopan para el tratamiento de la nefritis lupica. | |
| CO2025002794A2 (es) | Combinaciones de compuestos antineoplásicos que comprenden un compuesto bifuncional con actividad inhibitoria de kras mutante g12d | |
| WO2022081610A8 (en) | TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR | |
| CO2025002789A2 (es) | Combinaciones de agentes antineoplásicos que comprenden un compuesto bifuncional con actividad inhibitoria de kras mutante g12d | |
| WO2025051157A8 (zh) | 一种吡啶-2(1h)-酮类prmt5-mta抑制剂、其药物组合物及其应用 | |
| ZA202210474B (en) | Methods of treating sars-cov-2 infections | |
| MX2019010967A (es) | Agente terapeutico o profilactico para neuropatias perifericas. | |
| MX2023009810A (es) | Tratamientos para la hemofilia a. |